DNA and its associated processes as targets for cancer therapy

DNA is the molecular target for many of the drugs that are used in cancer therapeutics, and is viewed as a non-specific target of cytotoxic agents. Although this is true for traditional chemotherapeutics, other agents that were discovered more recently have shown enhanced efficacy. Furthermore, a new generation of agents that target DNA-associated processes are anticipated to be far more specific and effective. How have these agents evolved, and what are their molecular targets?

[1]  J. Trauger,et al.  Extension of sequence-specific recognition in the minor groove of DNA by pyrrole-imidazole polyamides to 9-13 base pairs , 1996 .

[2]  K. Nakanishi,et al.  Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. , 1987, Science.

[3]  C Zimmer,et al.  Nonintercalating DNA-binding ligands: specificity of the interaction and their use as tools in biophysical, biochemical and biological investigations of the genetic material. , 1986, Progress in biophysics and molecular biology.

[4]  L. Hurley,et al.  Pluramycins. Old Drugs Having Modern Friends in Structural Biology , 1996 .

[5]  F. Gago,et al.  Increased DNA binding specificity for antitumor ecteinascidin 743 through protein-DNA interactions? , 2000, Journal of medicinal chemistry.

[6]  P. Dervan,et al.  A Pyrrole‐Imidazole Polyamide Motif for Recognition of Eleven Base Pair Sequences in the Minor Groove of DNA , 1997 .

[7]  C. Hélène,et al.  Sequence-selective recognition and cleavage of double-helical DNA. , 1993, Current opinion in biotechnology.

[8]  R. J. GOLDACRE,et al.  Mode of Production of Chromosome Abnormalities by the Nitrogen Mustards The Possible Role of Cross-Linking , 1949, Nature.

[9]  P. Dervan,et al.  Chemical approaches to control gene expression. , 2000, Gene expression.

[10]  K. Ward.  The Chlorinated Ethylamines—A New Type of Vesicant , 1935 .

[11]  J. Nitiss.  Investigating the biological functions of DNA topoisomerases in eukaryotic cells. , 1998, Biochimica et biophysica acta.

[12]  J. Milligan,et al.  Triple helix DNA alters nucleosomal histone-DNA interactions and acts as a nucleosome barrier. , 1995, Nucleic acids research.

[13]  A. Bhathena,et al.  Glutathione S-transferases in wild-type and doxorubicin-resistant MCF-7 human breast cancer cell lines. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[14]  R. Bürli,et al.  Sequence-specific DNA recognition by polyamides. , 1999, Current opinion in chemical biology.

[15]  S. Smith.  Technology evaluation: SGN-15, Seattle Genetics Inc. , 2001, Current opinion in molecular therapeutics.

[16]  J. Portugal.  Drug interactions with nucleosomes and chromatin. , 2001, Methods in enzymology.

[17]  P. Dervan,et al.  Sequence specific alkylation of DNA by hairpin pyrrole-imidazole polyamide conjugates. , 2000, Chemistry & biology.

[18]  J G Pelton,et al.  Structural characterization of a 2:1 distamycin A.d(CGCAAATTGGC) complex by two-dimensional NMR. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Cunningham,et al.  Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Davies,et al.  Helix formation by guanylic acid. , 1962, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. Hurley,et al.  Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. , 1999, Journal of medicinal chemistry.

[22]  Y. Pommier,et al.  Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair , 2001, Nature Medicine.

[23]  C. Benham,et al.  AT-rich Islands in Genomic DNA as a Novel Target for AT-specific DNA-reactive Antitumor Drugs* 210 , 2001, The Journal of Biological Chemistry.

[24]  O. Cuvier,et al.  Specific gain- and loss-of-function phenotypes induced by satellite-specific DNA-binding drugs fed to Drosophila melanogaster. , 2000, Molecular cell.

[25]  D. Bearss,et al.  The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. , 2001, Chemistry & biology.

[26]  S. Jin,et al.  Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  K. Kohn,et al.  Cross-Linking : History and Prospects of DNA-targeted Cancer Treatment†” Fifteenth , 2006 .

[28]  P. Dervan,et al.  Molecular recognition of DNA by small molecules. , 2001, Bioorganic & medicinal chemistry.

[29]  D M Crothers,et al.  Studies of the binding of actinomycin and related compounds to DNA. , 1968, Journal of molecular biology.

[30]  L. Doucette‐Stamm,et al.  Site-specific cleavage of human chromosome 4 mediated by triple-helix formation. , 1991, Science.

[31]  D. Langley,et al.  Selective interactions of cationic porphyrins with G-quadruplex structures. , 2001, Journal of the American Chemical Society.

[32]  K. Syrigos,et al.  Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. , 1999, Anticancer research.

[33]  N. Maizels,et al.  The Saccharomyces cerevisiae Sgs1 helicase efficiently unwinds G-G paired DNAs. , 1999, Nucleic acids research.

[34]  S. Neidle,et al.  Inhibition of human telomerase by a G-quadruplex-interactive compound. , 1997, Journal of medicinal chemistry.

[35]  P. Glazer,et al.  Targeted gene knockout mediated by triple helix forming oligonucleotides , 1998, Nature Genetics.

[36]  L. Hurley,et al.  Monoalkylation and cross-linking of DNA by cyclopropapyrroloindoles entraps bent and straight forms of A-tracts , 1995 .

[37]  L. Liu,et al.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. , 1984, Science.

[38]  L. Hurley,et al.  Cooperative bending of the 21-base-pair repeats of the SV40 viral early promoter by human Sp1. , 1994, Biochemistry.

[39]  O. Fedoroff,et al.  Induction of Duplex to G-quadruplex Transition in the c-myc Promoter Region by a Small Molecule* , 2001, The Journal of Biological Chemistry.

[40]  C. Giovannangeli,et al.  Triplex-forming molecules for modulation of DNA information processing. , 2000, Current opinion in molecular therapeutics.

[41]  K. Kohn,et al.  Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II. , 1986, Biochemistry.

[42]  S. Lippard,et al.  Structure, Recognition, and Processing of Cisplatin-DNA Adducts. , 1999, Chemical reviews.

[43]  D. V. Von Hoff,et al.  7- and 10-substituted camptothecins: dependence of topoisomerase I-DNA cleavable complex formation and stability on the 7- and 10-substituents. , 2000, Molecular pharmacology.

[44]  Jean-Louis Mergny,et al.  G-quadruplex DNA: A target for drug design , 1998, Nature Medicine.

[45]  B. Teicher.  Cancer Therapeutics: Experimental And Clinical Agents , 1997, Nature Medicine.

[46]  K. Luger,et al.  Sequence-specific recognition of DNA in the nucleosome by pyrrole-imidazole polyamides. , 2001, Journal of molecular biology.

[47]  E. Reed.  Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. , 1998, Cancer treatment reviews.

[48]  M. Guéron,et al.  A tetrameric DNA structure with protonated cytosine-cytosine base pairs , 1993, Nature.

[49]  A. Schnapp,et al.  A highly selective telomerase inhibitor limiting human cancer cell proliferation , 2001, The EMBO journal.

[50]  L. Hurley,et al.  G-quadruplex DNA: a potential target for anti-cancer drug design. , 2000, Trends in pharmacological sciences.

[51]  J. Sedivy,et al.  A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation. , 2001, Cancer research.

[52]  L. Hurley,et al.  Molecular struggle for transcriptional control , 1995, Nature Genetics.

[53]  L. Hurley,et al.  Molecular Basis for the DNA Sequence Selectivity of Ecteinascidin 736 and 743: Evidence for the Dominant Role of Direct Readout via Hydrogen Bonding , 1998 .

[54]  C. Giovannangeli,et al.  Triplex technology takes off , 2000, Nature Biotechnology.

[55]  A. Gilman,et al.  The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides. , 1946, Science.

[56]  M. Stevens,et al.  Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. , 1995, Journal of medicinal chemistry.

[57]  R. Mantovani,et al.  Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[58]  D. V. Von Hoff,et al.  Design and synthesis of fluoroquinophenoxazines that interact with human telomeric G-quadruplexes and their biological effects. , 2001, Molecular cancer therapeutics.

[59]  H. M. Sobell,et al.  Stereochemistry of actinomycin--DNA binding. , 1971, Nature: New biology.

[60]  S. Neidle,et al.  The molecular basis for the action of some DNA-binding drugs. , 1979, Progress in medicinal chemistry.

[61]  A. Zewail,et al.  Femtosecond dynamics of a drug–protein complex: Daunomycin with Apo riboflavin-binding protein , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Y. Pommier.  DNA Topoisomerase II Inhibitors , 1997 .

[63]  P. Pečinka,et al.  DNA tetraplex formation in the control region of c-myc. , 1998, Nucleic acids research.

[64]  Margaret A. Strong,et al.  The Shortest Telomere, Not Average Telomere Length, Is Critical for Cell Viability and Chromosome Stability , 2001, Cell.

[65]  P. Nielsen.  Peptide nucleic acids as therapeutic agents. , 1999, Current opinion in structural biology.

[66]  T. Cech,et al.  The β subunit of Oxytricha telomere-binding protein promotes G-quartet formation by telomeric DNA , 1993, Cell.

[67]  L. Goodman,et al.  NITROGEN MUSTARD THERAPY: Use of Methyl-Bis(Beta-Chloroethyl)amine Hydrochloride and Tris(Beta-Chloroethyl)amine Hydrochloride for Hodgkin's Disease, Lymphosarcoma, Leukemia and Certain Allied and Miscellaneous Disorders , 1946 .

[68]  P. Nielsen,et al.  Double duplex invasion by peptide nucleic acid: a general principle for sequence-specific targeting of double-stranded DNA. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[69]  L. Kanter,et al.  Nitrogen mustard therapy; clinical studies on the effects of methyl-bis (beta-chloroethyl) amine hydrochloride upon various types of neoplastic disease. , 1949, American journal of surgery.

[70]  Y. Pommier,et al.  Topoisomerase I-mediated DNA damage. , 2001, Advances in cancer research.

[71]  M. Kuwahara,et al.  Design and Optimization of Camptothecin Conjugates of Triple Helix-forming Oligonucleotides for Sequence-specific DNA Cleavage by Topoisomerase I* , 2002, The Journal of Biological Chemistry.

[72]  P. Dervan,et al.  Inhibition of major-groove-binding proteins by pyrrole-imidazole polyamides with an Arg-Pro-Arg positive patch. , 1998, Chemistry & biology.

[73]  M D'Incalci,et al.  Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. , 2001, European journal of cancer.

[74]  S. Lippard,et al.  DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). , 1991, Biochemistry.

[75]  D. K. Treiber,et al.  Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[76]  S. Lippard,et al.  Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. , 1993, Science.

[77]  H. Sugiyama,et al.  Rational Design of Sequence-Specific DNA Alkylating Agents Based on Duocarmycin A and Pyrrole−Imidazole Hairpin Polyamides , 1999 .

[78]  B. M. Forman,et al.  The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux , 2001, Nature Medicine.

[79]  Max A. Keniry,et al.  Quadruplex structures in nucleic acids , 2000, Biopolymers.

[80]  M. Broggini,et al.  Modulation of transcription factor--DNA interactions by anticancer drugs. , 1994, Anti-cancer drug design.

[81]  M. Czyz,et al.  Transcription factors as targets of anticancer drugs. , 1999, Acta biochimica Polonica.

[82]  N. Thuong,et al.  Sequence‐Specific Recognition and Modification of Double‐Helical DNA by Oligonucleotides , 1993 .

[83]  BARNETT ROSENBERG,et al.  Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode , 1965, Nature.

[84]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[85]  D. V. Hoff,et al.  Cancer chemotherapy handbook , 1980 .

[86]  E. Reich,et al.  Actinomycin and nucleic acid function. , 1964, Progress in nucleic acid research and molecular biology.

[87]  Glenn B. Infield,et al.  Disaster at Bari , 1971 .

[88]  Paul A. Keifer,et al.  Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata , 1990 .